ArticleQuantitative imaging in medicine and surgery2026
Diagnostic value of subtraction CT in evaluating the efficacy of transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients compared to conventional CT and MRI.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transcatheter arterial chemoembolization (TACE) is a first-line treatment for hepatocellular carcinoma (HCC). However, the evaluation of tumor viability after treatment with conventional computed tomography (CT) or magnetic resonance imaging (MRI) is often hampered by iodized oil-induced artifacts. Subtraction CT may improve visualization by removing high-density materials. This study evaluates the diagnostic performance of subtraction CT compared to conventional CT and MRI in assessing efficacy of TACE in patients with HCC. Methods: Ninety-nine pathologically confirmed HCC patients (123 tumors) who underwent TACE treatment were retrospectively collected. Two radiologists assessed the tumors viability (viable, equivocal and nonviable) and diagnostic confidence in multiphase enhanced CT images (group A), multiphase enhanced CT with subtraction images (group B) and multiphase enhanced MRI images (group C). Tumor viability during TACE treatment was used as the reference standard. Sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) were compared among the groups using Chi-squared test. Kruskal-Wallis test evaluated the diagnostic confidence among the groups. Results: For tumors >5 mm, group B showed significantly higher sensitivity (90.5% Conclusions: Multiphase enhanced CT with subtraction images improves the diagnostic performance in evaluating the efficacy of TACE-treated HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.